HIVhepatitis

HIV hepatitis refers to the co-infection of the human immunodeficiency virus (HIV) with hepatitis viruses, most commonly hepatitis B virus (HBV) and hepatitis C virus (HCV). Individuals living with HIV are at a higher risk of acquiring and experiencing more severe outcomes from hepatitis infections compared to those without HIV.

HIV and hepatitis B can be transmitted through similar routes, including sexual contact and blood exposure, leading to a significant overlap in the affected populations. Co-infection with HIV and HBV can accelerate the progression of liver disease, increasing the likelihood of cirrhosis and liver cancer. Antiretroviral therapy for HIV can also have activity against HBV, and treatment for HBV is often recommended for co-infected individuals.

Hepatitis C is also primarily transmitted through blood exposure, and injection drug use is a major route of transmission for both HIV and HCV. HIV/HCV co-infection is associated with faster progression to liver fibrosis, cirrhosis, and liver failure. Effective treatments for HCV, including direct-acting antivirals (DAAs), can cure hepatitis C, and these treatments are generally safe and effective in people with HIV.

Managing HIV hepatitis involves a comprehensive approach that includes HIV treatment, management of the specific hepatitis virus infection, and regular monitoring of liver health. Early diagnosis and treatment are crucial to prevent or delay the development of serious liver complications. Public health efforts focus on prevention strategies such as vaccination against hepatitis B, safe injection practices, and harm reduction services.